Trial Profile
A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Pharmacodynamics
- Sponsors Sanofi
- 05 Apr 2017 Planned End Date changed from 1 Apr 2018 to 31 Mar 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 31 Mar 2017.
- 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment due to slow recruitment.